{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04221997",
            "orgStudyIdInfo": {
                "id": "Strawn EV-SoPRANO"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01HD098757",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01HD098757"
                }
            ],
            "organization": {
                "fullName": "University of Cincinnati",
                "class": "OTHER"
            },
            "briefTitle": "Trial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders.",
            "officialTitle": "Extracellular Vesicles as Predictors of Antidepressant Outcomes in Pediatric Anxiety (EV-SOPRANO)",
            "acronym": "EV-SoPRANO",
            "therapeuticArea": [
                "Mental Health"
            ],
            "study": "trial-with-the-treatment-of-sertraline-in-youth-with-generalized-separation-and-or-social-anxiety-disorders"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-11-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-01-06",
            "studyFirstSubmitQcDate": "2020-01-06",
            "studyFirstPostDateStruct": {
                "date": "2020-01-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-09-13",
            "lastUpdatePostDateStruct": {
                "date": "2023-09-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Jeffrey Strawn, MD",
                "investigatorTitle": "Associate professor",
                "investigatorAffiliation": "University of Cincinnati"
            },
            "leadSponsor": {
                "name": "University of Cincinnati",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "A Multicenter, acute, randomized, double-blind, placebo-controlled, flexible-dose trial with the treatment of sertraline.",
            "detailedDescription": "Randomized, double-blind, placebo-controlled trial of an evidence-based antidepressant, sertraline, in youth (N=120) with generalized, separation and/or social anxiety disorders, seeks to evaluate the predictive value of plasma EV signatures. Patients will be randomized to sertraline (25-200 mg/day) or placebo (3:1) and total plasma EVs will be collected at baseline and serially during the course of the 12-week treatment period."
        },
        "conditionsModule": {
            "conditions": [
                "Anxiety Disorders"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "During the acute treatment phase, 90 patients will be randomized to sertraline and 30 patients will be randomized to placebo (3:1).",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "maskingDescription": "Double Blind",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 150,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "sertraline",
                    "type": "EXPERIMENTAL",
                    "description": "90 patients will be randomized to sertraline",
                    "interventionNames": [
                        "Drug: sertraline"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "30 patient will be randomized to placebo",
                    "interventionNames": [
                        "Drug: sertraline"
                    ]
                },
                {
                    "label": "Healthy Control",
                    "type": "NO_INTERVENTION",
                    "description": "30 healthy comparison subjects will be followed over the course of 12 weeks"
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "sertraline",
                    "description": "Sertraline is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs)",
                    "armGroupLabels": [
                        "Placebo",
                        "sertraline"
                    ],
                    "otherNames": [
                        "Zoloft"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants with Clinical Global Impression-Improvement Scale \u2264 2",
                    "description": "Primary response outcome will be treatment response based on patients having attained a score on the Clinical Global Impression-Improvement Scale \u2264 2 at Week 12 or Last-Observation-Carried-Forward (LOCF).",
                    "timeFrame": "Week 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria for Patients with Anxiety :\n\n* Written, informed assent and consent.\n* Patients, parent/guardian/LAR must be fluent in the English.\n* 8-17 years of age, inclusive, at Visit 1, and who have a parent/guardian/LAR.\n* Patients must meet DSM-5 criteria for generalized, social and/or separation anxiety disorder, confirmed by the MINI-KID with no lifetime history of mania, OCD or significant history of trauma exposure.\n* PARS score \u226515 at Visits 1 and 2.\n* Caregiver who is willing to consent to be responsible for safety monitoring of the patient, provide information about the patient's condition, oversee the administration of the investigational product.\n* No clinically significant abnormalities on physical examination.\n* Negative pregnancy test at Visit 1 in females.\n* Sexually active patients must practice a reliable method of contraception (Section 15.0) that will continue for the duration of the study and within 30 days following the end of study participation.\n* Reliable methods of contraception are defined below; other forms of contraceptives (pharmacological and/or non-pharmacological) are not accepted.\n\n  * surgical sterilization\n  * oral contraceptives (e.g., estrogen-progestin combination or progestin)\n  * transdermally-delivered contraceptives (e.g., Ortho-Evra), depot injections (e.g.,\n  * Depo-Provera)\n  * vaginal contraceptive ring (e.g., NuvaRing), contraceptive implants (e.g., Implanon, Norplant\n  * II/Jadelle)\n  * an intrauterine device or\n  * diaphragm plus condom.\n\nInclusion Criteria for Healthy Controls:\n\n* Written, informed assent and consent.\n* Patients, parent/guardian/LAR must be fluent in the English.\n* 8 to 17 years of age, inclusive, at Visit 1, and who have a parent/guardian/LAR.\n* No history of any DSM-5 disorders (nicotine use disorder is permitted, history of adjustment disorder is permitted), confirmed by the MINI-KID.\n* Caregiver who is willing to consent to be responsible for safety monitoring of the patient, provide information about the patient.\n* No clinically significant abnormalities on physical examination. Negative pregnancy test at Screening in females.\n* Negative urine drug screen at Screening.\n* No first-degree relatives with an affective, anxiety or psychotic disorder.\n\nExclusion Criteria for Patients with Anxiety Disorders and Healthy Comparison:\n\n* Subjects Co-occurring DSM-5 diagnosis mood (except persistent depressive disorder, unspecified depressive disorder or co- occurring anxiety disorders, provided that the primary diagnosis is generalized, social and/or separation anxiety disorder(s)), eating, bipolar, or psychotic disorders.\n* A history of treatment with SSRIs within 12 weeks of Visit 2 (Baseline) or current pharmacotherapy with CNS effects that require \\>5 half-lives for discontinuation.\n* A history of major neurological or medical illness or head trauma with loss of consciousness for \u22655 minutes.\n* Lifetime history of mania, OCD, or significant history of trauma exposure.\n* History of hypersensitivity to sertraline.\n* Lifetime diagnosis of intellectual disability or history of IQ \\<70.\n* History of alcohol/substance use disorder or any substance abuse within the past 6 months (nicotine dependence is permitted).\n* Current psychotherapy stable for \\<2 months prior to Visit 2 (Baseline).\n* Females will not be eligible to participate if they are pregnant, breast feeding or lactating.\n* The subject lives \\>100 miles from the University of Cincinnati or \\>90 minutes from the CU site or is not able to attend the follow-up visits.\n* Patients who are unable to swallow capsules.\n* Is currently considered at risk of suicide in the opinion of the investigator, represents an inappropriate risk to the participant and/or could confound the interpretation of the study results.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "8 Years",
            "maximumAge": "17 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Heidi K Schroeder, BS",
                    "role": "CONTACT",
                    "phone": "513-558-4422",
                    "email": "heysehk@uc.edu"
                },
                {
                    "name": "Zoe A Neptune, BS",
                    "role": "CONTACT",
                    "phone": "513-558-2866",
                    "email": "neptunza@uc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jeffrey R Strawn, MD, FAACAP",
                    "affiliation": "University of Cincinnati",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Columbia, New York State Psychiatric Institute",
                    "status": "WITHDRAWN",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University of Cincinnati",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45219",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Heidi K Schroeder, BS",
                            "role": "CONTACT",
                            "phone": "513-558-4422",
                            "email": "heysehk@uc.edu"
                        },
                        {
                            "name": "Jeffrey R Strawn, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001008",
                    "term": "Anxiety Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4324",
                    "name": "Anxiety Disorders",
                    "asFound": "Anxiety Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1117",
                    "name": "Phobia, Social",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000020280",
                    "term": "Sertraline"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000928",
                    "term": "Antidepressive Agents"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000017367",
                    "term": "Selective Serotonin Reuptake Inhibitors"
                },
                {
                    "id": "D000014179",
                    "term": "Neurotransmitter Uptake Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000018490",
                    "term": "Serotonin Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15512",
                    "name": "Serotonin",
                    "relevance": "LOW"
                },
                {
                    "id": "M19649",
                    "name": "Selective Serotonin Reuptake Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M22100",
                    "name": "Sertraline",
                    "asFound": "Thyroid",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4247",
                    "name": "Antidepressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                }
            ]
        }
    },
    "hasResults": false
}